GSK (GSK) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for GSK despite higher revenues, with a focus on how actual results will compare to estimates [1][3]. Earnings Expectations - GSK is expected to report quarterly earnings of $1.26 per share, reflecting a -0.8% change year-over-year, while revenues are projected to be $11.2 billion, an increase of 7.5% from the previous year [3]. - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [4]. Earnings Surprise Potential - GSK's Most Accurate Estimate is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +0.63%, suggesting a likelihood of beating the consensus EPS estimate [12]. - The stock currently holds a Zacks Rank of 2, further supporting the potential for an earnings beat [12]. Historical Performance - GSK has consistently surpassed consensus EPS estimates, achieving this in the last four quarters, including a +9.82% surprise in the most recent quarter [13][14]. Industry Context - Incyte, a peer in the biomedical and genetics industry, is expected to report earnings of $1.66 per share, a +55.1% year-over-year change, with revenues projected at $1.26 billion, up 10.3% [18]. - Incyte's consensus EPS estimate has been revised 0.1% higher recently, resulting in an Earnings ESP of +3.48%, indicating a strong likelihood of beating the consensus [19].